This page is for healthcare professionals. It collects short summaries of recent studies and developments in radiation oncology, with a link to the original paper for each one. It is updated as notable studies are published. For patient information, please see the other pages on this site.
About these updates
Each update gives the study name or topic, where it was published, the key numbers, and a short note on what it may mean for practice — including what the study does not prove. Summaries are brief and are not a substitute for reading the full paper or for clinical judgement.
Endometrial cancer: molecular types and radiotherapy
Topic summary · ESGO–ESTRO–ESP 2025 · PORTEC-3 · PORTEC-4a · RAINBO
How the four molecular types (POLEmut, MMRd, NSMP, p53abn) change the risk group and the adjuvant radiotherapy decision — who can omit treatment, who needs brachytherapy or pelvic EBRT, and who needs chemoradiation.
MASTERPLAN trial: SBRT in pancreatic cancer
Lancet Oncology · Oct 2026 · Randomised phase II · ESMO 2026
Adding SBRT (40 Gy in 5 fractions) to chemotherapy halved 12-month locoregional recurrence — 20.2% vs 52.0% — in high-risk localised pancreatic cancer, with a survival signal that needs phase III confirmation.
HARVEST trial
Int J Radiat Oncol Biol Phys · Nov 2026 · Phase III
Hypofractionated vs conventional breast radiotherapy, both with comprehensive regional nodal irradiation including the internal mammary nodes.
What it doesn’t prove: Early toxicity data only — long-term cancer control and late effects, including cardiac effects, are still awaited.
Full paper: DOI 10.1016/j.ijrobp.2026.10.050
IDEA trial, long-term follow-up
JAMA Oncology · Nov 2026 · Single-arm prospective study
Endocrine therapy alone, no radiotherapy after breast-conserving surgery, in postmenopausal patients aged 50–69 with stage I ER-positive, HER2-negative cancer and Oncotype RS ≤18.
What it doesn’t prove: Single-arm study with no radiotherapy comparison group — results depend on patients continuing endocrine therapy.
Full paper: DOI 10.1001/jamaoncol.2026.4529
SRAM trial, 12-month update
Radiotherapy and Oncology · Nov 2026 · Randomised phase II
Pelvis-inclusive SBRT (40 Gy prostate / 25 Gy pelvis in 5 once-weekly fractions) vs IMRT (76 Gy in 38 fractions) in high-risk prostate cancer.
What it doesn’t prove: Phase II, 121 patients — cancer-control outcomes are not yet reported.
Full paper: DOI 10.1016/j.radonc.2026.111870
Staying up to date
Short summaries of selected studies are also shared on LinkedIn as they are published. Healthcare professionals are welcome to get in touch via the Contact page about referrals, second opinions, or collaboration.
This page is for healthcare professionals and is general information only. It does not replace the full text of the cited studies, clinical guidelines, or individual clinical judgement.